We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.52%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$449M
AUM Growth
+$34.2M
Cap. Flow
+$72.9M
Cap. Flow %
16.24%
Top 10 Hldgs %
46.73%
Holding
81
New
13
Increased
18
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
EXC icon
Exelon
EXC
+$28.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.85M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$9.77M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$9.45M
5
ONC
BeOne Medicines Ltd
ONC
+$6.75M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.1M
2
EXEL icon
Exelixis
EXEL
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$8.27M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.64M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 97.78%
2 Utilities 2.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$4.87B
$5.64M 1.26%
476,000
+226,000
+90% +$3.18M
JAZZ icon
27
Jazz Pharmaceuticals
JAZZ
$16.3B
$5.63M 1.25%
44,200
– –
ONC
28
BeOne Medicines Ltd
ONC
$42.1B
$5.4M 1.2%
+20,000
New +$6.75M
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
$5.07M 1.13%
383,233
– –
KDNY
30
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.71M 1.05%
289,389
+54,389
+23% +$774K
ASND icon
31
Ascendis Pharma A/S
ASND
$16.4B
$3.96M 0.88%
29,400
– –
INSM icon
32
Insmed
INSM
$26.5B
$3.3M 0.74%
121,100
-120,000
-50% -$3.43M
QURE icon
33
uniQure
QURE
$3.44B
$3.23M 0.72%
155,500
-26,694
-15% -$766K
VERA icon
34
Vera Therapeutics
VERA
$2.49B
$3.2M 0.71%
+120,535
New +$2.67M
KRYS icon
35
Krystal Biotech
KRYS
$10.6B
$3.15M 0.7%
+45,000
New +$2.62M
TPTX
36
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.94M 0.66%
61,741
-77,000
-55% -$3.44M
NTLA icon
37
Intellia Therapeutics
NTLA
$1.84B
$2.84M 0.63%
+24,000
New +$3.01M
GBT
38
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.77M 0.62%
94,800
+73,000
+335% +$2.26M
IDYA icon
39
IDEAYA Biosciences
IDYA
$4.03B
$2.58M 0.57%
109,000
– –
ZLAB icon
40
Zai Lab
ZLAB
$3.01B
$2.45M 0.55%
38,958
– –
HCM icon
41
HUTCHMED
HCM
$2.16B
$2.38M 0.53%
68,000
– –
ORIC icon
42
Oric Pharmaceuticals
ORIC
$1.42B
$2.25M 0.5%
153,000
+100,000
+189% +$1.56M
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
$2.19M 0.49%
135,000
– –
BPMC
44
DELISTED
Blueprint Medicines
BPMC
$2.09M 0.47%
19,500
– –
STRO icon
45
Sutro Biopharma
STRO
$353M
$2.07M 0.46%
13,933
– –
ARNA
46
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.95M 0.43%
21,000
– –
FATE icon
47
Fate Therapeutics
FATE
$304M
$1.64M 0.36%
28,000
– –
HARP
48
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.62M 0.36%
21,500
– –
SWTX
49
DELISTED
SpringWorks Therapeutics
SWTX
$1.55M 0.35%
25,000
– –
APLS
50
DELISTED
Apellis Pharmaceuticals
APLS
$1.54M 0.34%
+32,500
New +$1.28M
1
2
3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2021 Portfolio in Review

As of Q4 2021, International Biotechnology Trust held 81 positions worth $449M, up 8.3% from $415M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust deployed $72.9M of net new capital in Q4 2021, opening 13 new positions and adding to 18 existing holdings. Its largest new stake was Exelon: 766,241 shares worth $9.98M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Utilities.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $15.1M trimmed.

  • International Biotechnology Trust's largest Q4 2021 buy was Exelon: 766,241 shares worth $9.98M.
  • International Biotechnology Trust added most to Alnylam Pharmaceuticals in Q4 2021, an estimated $9.85M increase.
  • International Biotechnology Trust's biggest Q4 2021 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $15.1M.
  • International Biotechnology Trust fully exited Exelixis in Q4 2021, selling an estimated $10.3M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $449M portfolio in Q4 2021.
  • International Biotechnology Trust opened 13 new positions and closed 8 in Q4 2021.
  • International Biotechnology Trust's portfolio value rose 8.3% quarter-over-quarter to $449M.

Based on International Biotechnology Trust's 13F filing for Q4 2021, filed 15 Feb 2022.